Upstream & Downstream Processing

GE and Guangzhou gov bring bioprocess training to China

A single-use bioprocessing training facility in Guangzhou will help attract and retain biopharma talent in the burgeoning China market, says GE Healthcare. Bioprocess vendor GE Healthcare Life Sciences and Guangzhou Development District government have invested a total of $10 million (€9 million) to establish a biomanufacturing training center in the Guangdong province in China. The Guangzhou Bioprocess Academy aims to train over 1,000 people annually when it opens in September next year and is needed to feed the the rapid…

$50m deal helps make Sartorius a media player again

A year after ending an exclusive collaboration with Lonza for cell culture media and buffers, Sartorius has reentered the space by acquiring 50% of Israeli firm Biological Industries The deal sees bioprocess equipment and consumables vendor Sartorius pay €45 million ($50 million) in cash to Kibbutz Beit Haemek and private equity fund Fortissimo Capital for just over half of Biological Industries. Under terms of the deal, Sartorius will have the option to acquire a further 20% of the Haifa, Israel-based…

Polyplus ups reagent range to support growing CGT space

Polyplus-transfection SA has expanded its reagent portfolio, citing the growing number of candidate cell and gene therapies nearing commercialization as the driver. The French biotech launched a range of sizes of its PEIpro-GMP reagent in single-use bags and bottles this week. Transfection reagents facilitate cellular uptake of nucleic acids. Polyplus premiered PEIpro-GMP last year, marketing it as “the first transfection solution for the gene and cell therapy industry that is compliant with global cGMP viral vector manufacturing requirements.” The expanded…

Saint-Gobain completes Florida plant as part of $77m global expansion

French vendor Saint-Gobain has completed construction of a tubing plant in Florida, the second of seven manufacturing expansions intended to support the rapidly growing bioprocess space. The 80,000 square-foot facility in Largo, Florida is set to increase Saint-Gobain’s manufacturing capacity for its C-Flex tubing and assemblies used in fluid management for biomanufacturing. The plant, which is soon to be operational, has created up to 20 new jobs. But for Saint-Gobain, the facility completion marks the second part of seven of…

GE bolsters off-the-shelf facility offering in Pharmadule deal

GE Healthcare has entered into a partnership with Pharmadule Morimatsu to optimize and expand supply of its off-the-shelf biomanufacturing platform, KUBio. Demand for modular off-the-shelf manufacturing platforms is high, due to the speed of construction and operation, flexible use, and capital cost-saving. One of the suppliers of such technologies is GE Healthcare, which touts its KUBio platform as a “factory in a box,” capable of producing biologics, vaccines, viral vector-based therapies, and other modalities. Now the bioprocess vendor has teamed…

Purolite resin booming on biopharma uptake and ‘major’ regulatory milestone

The US FDA has approved a manufacturing process using a Purolite Praesto resin for the first time. Purolite says Janssen, Celgene and Biogen are among the firms working with its Praesto range of mAb capture resins. The separation tech firm told Bioprocess Insider about demand for its products last week, explaining that “Praesto resins are currently implemented into over 170 ongoing pre-clinical to Phase III projects at facilities across the globe. “This is a mix of standard and custom design…

Liminal divesting Prometic Bioseparations to KKR in $100m deal

Investment firm KKR is set to acquire Prometic Bioseparations, the chromatography and bioprocessing business of Liminal BioSciences. Global biotech firm Liminal BioSciences, which changed its name in September from Prometic Life Sciences, has announced the sale of Prometic Bioseparations (PBL) to KKR. The investment firm will pay £45 million ($58 million), with up to £32 million ($42 million) more upon closing of the deal. PBL offers chromatography columns and services for the biomanufacturing industry. Its Evolve Process column range offers…

MilliporeSigma: Over 90% growth comes from mAbs, despite new modality momentum

MilliporeSigma is seeing “terrific momentum” from the burgeoning cell and gene therapy space, but says double-digit growth continues to be driven by monoclonal antibodies (mAbs). The recent buzz in biopharma has been around the cell and gene therapy space, along with other modalities such as mRNA. It is no surprise that news outlets, such as this one, focus on ‘new’ modalities such as cell therapies, gene therapies, and mRNA. These are touted as the next-generation in treating and curing diseases,…

Avantor partners with NIBRT to take on biopharma bottlenecks

Avantor has teamed up with Ireland’s National Institute for Bioprocessing Research and Training (NIBRT) to develop solutions for “bottlenecks” that increase the cost and time it takes to make biopharmaceuticals. The collaboration – financial terms of which were not provided – will see Avantor install in-line dilution systems at NIBRT’s facility in Dublin, Ireland. The idea is to provide technicians with hands-on experience of the technology according to Killian O’Driscoll, NIBRT director of projects. “The in-line dilution technology will be…

Thermo to add culture media production capacity at Scotland site by 2021

Thermo Fisher Scientific will spend $24 million (€22 million) to up culture media capacity at its Inchinnan, Scotland facility. The firm said it will add large-volume liquid manufacturing capacity for cell culture media by 2021. Cory Stevenson, president of Thermo Fisher’s bioproduction business, said increased biopharmaceutical industry demand prompted the investment. “More and more customers are outsourcing their liquid manufacturing to ensure the highest quality while delivering efficiency.” “This investment will expand capabilities and expertise at our existing cell culture…